<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine variables associated with glycemic and body weight responses when adding exenatide to basal insulin-treated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Exenatide participants had greater A1C reductions compared with optimized insulin glargine alone, irrespective of baseline A1C (P &lt; 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>Exenatide participants with longer <z:mp ids='MP_0002055'>diabetes</z:mp> duration and those with lower BMI had greater A1C reductions (P &lt; 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>Exenatide participants lost more weight, regardless of baseline A1C or BMI (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Exenatide participants with longer <z:mp ids='MP_0002055'>diabetes</z:mp> duration lost the most weight (P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Exenatide added to optimized basal insulin was associated with improved glycemic control and <z:hpo ids='HP_0001824'>weight loss</z:hpo>, irrespective of baseline A1C, <z:mp ids='MP_0002055'>diabetes</z:mp> duration, and BMI </plain></SENT>
<SENT sid="7" pm="."><plain>Changes were evident in modestly <z:mp ids='MP_0001261'>obese</z:mp> patients and in those with longer <z:mp ids='MP_0002055'>diabetes</z:mp> duration </plain></SENT>
</text></document>